{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:29:26Z","timestamp":1789957766236,"version":"4.0.1"},"reference-count":369,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Behavioural Brain Research"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1016\/j.bbr.2009.06.008","type":"journal-article","created":{"date-parts":[[2009,6,11]],"date-time":"2009-06-11T05:03:14Z","timestamp":1244696594000},"page":"1-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":113,"title":["In vivo imaging of synaptic function in the central nervous system"],"prefix":"10.1016","volume":"204","author":[{"given":"Susanne","family":"Nikolaus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Antke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Wilhelm","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbr.2009.06.008_bib1","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1097\/WCO.0b013e3283168df0","article-title":"Dementia in Parkinson's disease","volume":"21","author":"Aarsland","year":"2008","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib2","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1093\/brain\/awh607","article-title":"PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation","volume":"128","author":"Adams","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.bbr.2009.06.008_bib3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/glia.1106","article-title":"Immune function of microglia","volume":"36","author":"Aloisi","year":"2001","journal-title":"Glia"},{"key":"10.1016\/j.bbr.2009.06.008_bib4","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1093\/brain\/122.12.2353","article-title":"Huntington's disease progression. PET and clinical observations","volume":"122","author":"Andrews","year":"1999","journal-title":"Brain"},{"key":"10.1016\/j.bbr.2009.06.008_bib5","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1212\/WNL.44.7.1325","article-title":"[11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: influence of l-DOPA and lisuride therapy on striatal dopamine D2-receptors","volume":"44","author":"Antonini","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.bbr.2009.06.008_bib6","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1001\/archneur.1995.00540360061017","article-title":"Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease","volume":"52","author":"Antonini","year":"1995","journal-title":"Arch Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib7","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/brain\/119.6.2085","article-title":"Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease","volume":"119","author":"Antonini","year":"1996","journal-title":"Brain"},{"key":"10.1016\/j.bbr.2009.06.008_bib8","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1093\/brain\/120.12.2187","article-title":"Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease","volume":"120","author":"Antonini","year":"1997","journal-title":"Brain"},{"key":"10.1016\/j.bbr.2009.06.008_bib9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/mds.870120107","article-title":"Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride","volume":"12","author":"Antonini","year":"1997","journal-title":"Mov Disord"},{"key":"10.1016\/j.bbr.2009.06.008_bib10","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ana.410430216","article-title":"[11C]raclopride-PET studies of the Huntington's disease rate of progression: relevance of the trinucleotide repeat length","volume":"43","author":"Antonini","year":"1998","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s100720170040","article-title":"The status of dopamine nerve terminals in Parkinson's disease and essential tremor: a PET study with the tracer [11-C]FE-CIT","volume":"22","author":"Antonini","year":"2001","journal-title":"Neurol Sci"},{"issue":"Suppl 2","key":"10.1016\/j.bbr.2009.06.008_bib12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s100720200065","article-title":"Striatal dopaminergic denervation in early and late onset Parkinson's disease assessed by PET and the tracer [11C]FECIT: preliminary findings in one patient with autosomal recessive parkinsonism (Park2)","volume":"23","author":"Antonini","year":"2002","journal-title":"Neurol Sci"},{"key":"10.1016\/j.bbr.2009.06.008_bib13","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10072-003-0103-5","article-title":"123I-Ioflupane\/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy","volume":"24","author":"Antonini","year":"2003","journal-title":"Neurol Sci"},{"key":"10.1016\/j.bbr.2009.06.008_bib14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-3-7091-6641-3_9","article-title":"Clinical progressive supranuclear palsy: differential diagnosis by IBZM-SPECT and MRI","volume":"42","author":"Arnold","year":"1994","journal-title":"J Neural Transm Suppl"},{"key":"10.1016\/j.bbr.2009.06.008_bib15","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/mds.10106","article-title":"Steele-Richardson-Olszewski-syndrome: reduction of dopamine D2 receptor binding relates to the severity of midbrain atrophy in vivo: (123)IBZM SPECT and MRI study","volume":"17","author":"Arnold","year":"2002","journal-title":"Mov Disord"},{"key":"10.1016\/j.bbr.2009.06.008_bib16","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s007020200041","article-title":"Steele-Richardson-Olszewski-syndrome: the relation of dopamine D2 receptor binding and subcortical lesions in MRI","volume":"109","author":"Arnold","year":"2002","journal-title":"J Neural Transm."},{"key":"10.1016\/j.bbr.2009.06.008_bib17","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1600-0404.1995.tb00443.x","article-title":"Hypersensitivity of cortical muscarinic receptors in Parkinson's disease demonstrated by PET","volume":"91","author":"Asahina","year":"1995","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.bbr.2009.06.008_bib18","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1136\/jnnp.65.2.155","article-title":"Brain muscarinic receptors in progressive supranuclear palsy and Parkinson's disease: a positron emission tomographic study","volume":"65","author":"Asahina","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.bbr.2009.06.008_bib19","first-page":"1","article-title":"Imaging of dopamine transporters with iodine-123-beta-CIT and SPECT in Parkinson's disease","volume":"38","author":"Asenbaum","year":"1997","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib20","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s007020050124","article-title":"[123I]beta-CIT and SPECT in essential tremor and Parkinson's disease","volume":"105","author":"Asenbaum","year":"1998","journal-title":"J Neural Transm"},{"key":"10.1016\/j.bbr.2009.06.008_bib21","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1093\/brain\/120.12.2207","article-title":"Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes","volume":"120","author":"Backman","year":"1997","journal-title":"Brain"},{"key":"10.1016\/j.bbr.2009.06.008_bib22","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1080\/09540260802099968","article-title":"Neuropsychiatric symptoms in dementia: importance and treatment considerations","volume":"20","author":"Ballard","year":"2008","journal-title":"Int Rev Psychiatry"},{"key":"10.1016\/j.bbr.2009.06.008_bib23","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/jcbfm.1986.26","article-title":"Loss of striatal [76Br]bromospiperone binding sites demonstrated by positron tomography in progressive supranuclear palsy","volume":"6","author":"Baron","year":"1986","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.bbr.2009.06.008_bib24","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12035-008-8031-2","article-title":"Therapeutic strategies for Alzheimer's disease","volume":"37","author":"Barten","year":"2008","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.bbr.2009.06.008_bib25","first-page":"163","article-title":"Neuropeptides in Alzheimer's disease","volume":"24","author":"Beal","year":"1987","journal-title":"J Neural Transm Suppl"},{"key":"10.1016\/j.bbr.2009.06.008_bib26","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/mds.20720","article-title":"Psychogenic parkinsonism: a combination of clinical, electrophysiological, and [(123)I]-FP-CIT SPECT scan explorations improves diagnostic accuracy","volume":"21","author":"Benaderette","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.bbr.2009.06.008_bib27","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/1531-8257(200005)15:3<503::AID-MDS1013>3.0.CO;2-V","article-title":"Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group","volume":"15","author":"Benamer","year":"2000","journal-title":"Mov Disord"},{"key":"10.1016\/j.bbr.2009.06.008_bib28","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/brain\/awn291","article-title":"Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study","volume":"132","author":"Bensimon","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.bbr.2009.06.008_bib29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1055\/s-0038-1623903","article-title":"[[123I]beta-CIT SPECT imaging of dopamine and serotonin transporters in Parkinson's disease and multiple system atrophy","volume":"42","author":"Berding","year":"2003","journal-title":"Nuklearmedizin"},{"key":"10.1016\/j.bbr.2009.06.008_bib30","first-page":"CD005593","article-title":"Cholinesterase inhibitors for Alzheimer's disease","volume":"1","author":"Birks","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bbr.2009.06.008_bib31","first-page":"CD001190","article-title":"Donepezil for dementia due to Alzheimer's disease","volume":"1","author":"Birks","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bbr.2009.06.008_bib32","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/brain\/116.3.497","article-title":"Loss of brain 5-HT2 receptors in Alzheimer's disease. In vivo assessment with positron emission tomography and [18F]setoperone","volume":"116","author":"Blin","year":"1993","journal-title":"Brain"},{"key":"10.1016\/j.bbr.2009.06.008_bib33","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1212\/WNL.54.9.1753","article-title":"Decreased striatal monoaminergic terminals in Huntington disease","volume":"54","author":"Bohnen","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.bbr.2009.06.008_bib34","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1001\/archneur.60.12.1745","article-title":"Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study","volume":"60","author":"Bohnen","year":"2003","journal-title":"Arch Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib35","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/sj.jcbfm.9600276","article-title":"Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease","volume":"26","author":"Bohnen","year":"2006","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.bbr.2009.06.008_bib36","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/mds.22212","article-title":"Elevated serotonin transporter binding in depressed patients with Parkinson's disease: a preliminary PET study with [11C]DASB","volume":"23","author":"Boileau","year":"2008","journal-title":"Mov Disord."},{"key":"10.1016\/j.bbr.2009.06.008_bib37","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1136\/jnnp.62.2.133","article-title":"[123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease","volume":"62","author":"Booij","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.bbr.2009.06.008_bib38","first-page":"674","article-title":"Assessment of endogenous dopamine release by methylphenidate challenge using iodine-123 iodobenzamide single-photon emission tomography","volume":"24","author":"Booij","year":"1997","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib39","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s002590000460","article-title":"The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism","volume":"28","author":"Booij","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib40","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jocn.2004.06.012","article-title":"Reduced posterior cingulate binding of I-123 iodo-dexetimide to muscarinic receptors in mild Alzheimer's disease","volume":"12","author":"Boundy","year":"2005","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.bbr.2009.06.008_bib41","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1176\/jnp.2.1.20","article-title":"D2 receptors in Huntington's disease: positron emission tomography findings and clinical correlates","volume":"2","author":"Brandt","year":"1990","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.bbr.2009.06.008_bib42","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00702-005-0311-7","article-title":"[(11)C]d-threo-methylphenidate PET in patients with Parkinson's disease and essential tremor","volume":"113","author":"Breit","year":"2006","journal-title":"J Neural Transm"},{"key":"10.1016\/j.bbr.2009.06.008_bib43","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/ana.410280412","article-title":"Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy","volume":"28","author":"Brooks","year":"1990","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib44","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/ana.410310209","article-title":"Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography","volume":"31","author":"Brooks","year":"1992","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib45","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0022-510X(99)00127-6","article-title":"The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson's disease","volume":"166","author":"Broussolle","year":"1999","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.bbr.2009.06.008_bib46","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1212\/WNL.55.6.877","article-title":"[18F]-DOPA PET study in patients with juvenile-onset PD and parkin gene mutations","volume":"55","author":"Broussolle","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.bbr.2009.06.008_bib47","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0022-3956(97)00031-9","article-title":"123Iodo-MK-801: a spect agent for imaging the pattern and extent of glutamate (NMDA) receptor activation in Alzheimer's disease","volume":"31","author":"Brown","year":"1997","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.bbr.2009.06.008_bib48","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s00259-002-1028-6","article-title":"Acetylcholine muscarinic receptors and response to anti-cholinesterase therapy in patients with Alzheimer's disease","volume":"30","author":"Brown","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.bbr.2009.06.008_bib49","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.neurobiolaging.2004.07.014","article-title":"Cortical 6-[18F]fluoro-l-DOPA uptake and frontal cognitive functions in early Parkinson's disease","volume":"26","author":"Br\u00fcck","year":"2005","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.bbr.2009.06.008_bib50","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/mds.20855","article-title":"Striatal subregional 6-[18F]fluoro-l-DOPA uptake in early Parkinson's disease: a two-year follow-up study","volume":"21","author":"Br\u00fcck","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.bbr.2009.06.008_bib51","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/jcbfm.1991.53","article-title":"Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders","volume":"11","author":"Br\u00fccke","year":"1991","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.bbr.2009.06.008_bib52","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/BF01245007","article-title":"SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT. Binding kinetics in the human brain","volume":"94","author":"Br\u00fccke","year":"1993","journal-title":"J Neural Transm Gen Sect"},{"key":"10.1016\/j.bbr.2009.06.008_bib53","first-page":"494","article-title":"Dopamine D2 receptor imaging and measurement with SPECT","volume":"60","author":"Br\u00fccke","year":"1993","journal-title":"Adv Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib54","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/978-3-7091-6842-4_2","article-title":"Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy","volume":"50","author":"Br\u00fccke","year":"1997","journal-title":"J Neural Transm Suppl"},{"key":"10.1016\/j.bbr.2009.06.008_bib55","first-page":"1196","article-title":"Iodine-123-IBF SPECT evaluation of extrapyramidal diseases","volume":"36","author":"Buck","year":"1995","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib56","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/jnnp.57.3.278","article-title":"Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data","volume":"57","author":"Burn","year":"1994","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.bbr.2009.06.008_bib57","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/brain\/118.4.951","article-title":"Striatal opioid receptor binding in Parkinson's disease, striatonigral degeneration and Steele-Richardson-Olszewski syndrome, A [11C]diprenorphine PET study","volume":"118","author":"Burn","year":"1995","journal-title":"Brain"},{"key":"10.1016\/j.bbr.2009.06.008_bib58","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0022-510X(83)90045-X","article-title":"Pathological changes in the nucleus of Meynert in Alzheimer's and Parkinson's diseases","volume":"59","author":"Candy","year":"1983","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.bbr.2009.06.008_bib59","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1468-1331.2006.01642.x","article-title":"Striatal dopamine transporter binding in patients with Parkinson's disease and severe occupational hydrocarbon exposure","volume":"14","author":"Canesi","year":"2007","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib60","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00702-007-0015-2","article-title":"Loss of thalamic serotonin transporters in early drug-na\u00efve Parkinson's disease patients is associated with tremor: an [(123)I]beta-CIT SPECT study","volume":"115","author":"Caretti","year":"2008","journal-title":"J Neural Transm"},{"key":"10.1016\/j.bbr.2009.06.008_bib61","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00702-004-0140-0","article-title":"Presynaptic nigro-striatal function in a group of Alzheimer's disease patients with parkinsonism: evidence from a dopamine transporter imaging study","volume":"111","author":"Ceravolo","year":"2004","journal-title":"J Neural Transm"},{"key":"10.1016\/j.bbr.2009.06.008_bib62","first-page":"1481","article-title":"In-vivo SPECT imaging of D2 receptor with iodine-iodolisuride: results in supranuclear palsy","volume":"33","author":"Chabriat","year":"1992","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib63","first-page":"221","article-title":"The killing of neurons by beta-amyloid peptides, prions, and pro-inflammatory cytokines","volume":"111","author":"Chiarini","year":"2006","journal-title":"Ital J Anat Embryol"},{"key":"10.1016\/j.bbr.2009.06.008_bib64","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1742-1241.1996.tb10025.x","article-title":"Progressive supranuclear palsy presenting with psychiatric features","volume":"50","author":"Chiu","year":"1996","journal-title":"Br J Clin Pract"},{"key":"10.1016\/j.bbr.2009.06.008_bib65","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3233\/JAD-2006-10112","article-title":"From tau to toxicity: emerging roles of NMDA receptor in Alzheimer's disease","volume":"10","author":"Chohan","year":"2006","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.bbr.2009.06.008_bib66","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1097\/00006231-200106000-00017","article-title":"Striatal dopamine transporter binding in early to moderately advanced Parkinson's disease: monitoring of disease progression over 2 years","volume":"22","author":"Chouker","year":"2001","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.bbr.2009.06.008_bib67","first-page":"602","article-title":"Demonstration of a reduction in muscarinic receptor binding in early Alzheimer's disease using iodine-123 dexetimide single-photon emission tomography","volume":"24","author":"Claus","year":"1997","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib68","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.neuroimage.2004.06.045","article-title":"The application of statistical parametric mapping to 123I-FP-CIT SPECT in dementia with Lewy bodies, Alzheimer's disease and Parkinson's disease","volume":"23","author":"Colloby","year":"2004","journal-title":"Neuroimage"},{"key":"10.1016\/j.bbr.2009.06.008_bib69","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1007\/s00259-005-1830-z","article-title":"Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia assessed using 123I-FP-CIT SPECT","volume":"32","author":"Colloby","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.bbr.2009.06.008_bib70","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.neuroimage.2006.07.026","article-title":"In vivo SPECT imaging of muscarinic acetylcholine receptors using (R,R) 123I-QNB in dementia with Lewy bodies and Parkinson's disease dementia","volume":"33","author":"Colloby","year":"2006","journal-title":"Neuroimage"},{"key":"10.1016\/j.bbr.2009.06.008_bib71","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1017\/S1041610208007709","article-title":"A comparison of 99mTc-exametazime and 123I-FP-CIT SPECT imaging in the differential diagnosis of Alzheimer's disease and dementia with Lewy bodies","volume":"20","author":"Colloby","year":"2008","journal-title":"Int Psychogeriatr"},{"key":"10.1016\/j.bbr.2009.06.008_bib72","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1055\/s-0038-1629599","article-title":"L-18F-dopa-PET in Parkinson-plus syndromes for the detection of a disordered presynaptic dopaminergic function","volume":"31","author":"Cordes","year":"1992","journal-title":"Nuklearmedizin"},{"key":"10.1016\/j.bbr.2009.06.008_bib73","first-page":"525","article-title":"IBZM-SPECT imaging in Parkinson's disease. Quantification of binding ratios from sequential SPECT measurements in patients and controls","volume":"60","author":"Cordes","year":"1993","journal-title":"Adv Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib74","first-page":"22","article-title":"Iodine-123-iodo-lisuride SPECT in Parkinson's disease","volume":"37","author":"Cordes","year":"1996","journal-title":"J Nucl Med"},{"issue":"Suppl 7","key":"10.1016\/j.bbr.2009.06.008_bib75","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1002\/mds.10576","article-title":"Dementia with Lewy bodies versus Alzheimer's disease: role of dopamine transporter imaging","volume":"18","author":"Costa","year":"2003","journal-title":"Mov Disord"},{"key":"10.1016\/j.bbr.2009.06.008_bib76","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.pscychresns.2007.11.003","article-title":"Pre- and post-synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with [11C]NNC 112 and [18F]FDOPA","volume":"163","author":"Cropley","year":"2008","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.bbr.2009.06.008_bib77","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0006-8993(87)90101-6","article-title":"Subtraction autoradiography of opiate receptor subtypes in human brain","volume":"418","author":"Cross","year":"1987","journal-title":"Brain Res"},{"key":"10.1016\/j.bbr.2009.06.008_bib78","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ana.65","article-title":"Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover","volume":"49","author":"de la Fuente-Fernandez","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib79","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1093\/brain\/awh290","article-title":"Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias","volume":"127","author":"de la Fuente-Fernandez","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.bbr.2009.06.008_bib80","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/1531-8257(199911)14:6<1025::AID-MDS1020>3.0.CO;2-P","article-title":"Striatal D2 dopamine receptor status in Parkinson's disease: an DOPA and [11C]raclopride PET study","volume":"14","author":"Dentresangle","year":"1999","journal-title":"Mov Disord"},{"issue":"Suppl 3","key":"10.1016\/j.bbr.2009.06.008_bib81","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/mds.10141","article-title":"Pathophysiology of nonparkinsonian tremors","volume":"17","author":"Deuschl","year":"2002","journal-title":"Mov Disord"},{"key":"10.1016\/j.bbr.2009.06.008_bib82","first-page":"209","article-title":"Combined FDOPA and 3OMFD PET studies in Parkinson's disease","volume":"37","author":"Dhawan","year":"1996","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib83","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/gps.1973","article-title":"A 6-month, open-label study of memantine in patients with frontotemporal dementia","volume":"23","author":"Diehl-Schmid","year":"2008","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.bbr.2009.06.008_bib84","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1212\/01.WNL.0000031424.51127.2B","article-title":"Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study","volume":"60","author":"Doder","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.bbr.2009.06.008_bib85","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/mds.21861","article-title":"Brain parenchyma sonography and 123I-FP-CIT SPECT in Parkinson's disease and essential tremor","volume":"23","author":"Doepp","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.bbr.2009.06.008_bib86","first-page":"320","article-title":"Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease","volume":"24","author":"Donnemiller","year":"1997","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib87","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/S1474-4422(07)70245-4","article-title":"Assessment of the progression of Parkinson's disease: a metabolic network approach","volume":"6","author":"Eckert","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib88","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.nbd.2008.08.001","article-title":"Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study","volume":"32","author":"Edison","year":"2008","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.bbr.2009.06.008_bib89","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00259-005-1920-y","article-title":"Quantitative simultaneous (99m)Tc-ECD\/123I-FP-CIT SPECT in Parkinson's disease and multiple system atrophy","volume":"33","author":"El Fakhri","year":"2006","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.bbr.2009.06.008_bib90","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.nlm.2008.05.006","article-title":"Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study","volume":"90","author":"Ellis","year":"2008","journal-title":"Neurobiol Learn Mem"},{"key":"10.1016\/j.bbr.2009.06.008_bib91","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/j.1532-5415.1996.tb02940.x","article-title":"Treatment of progressive supranuclear palsy with amitriptyline: therapeutic and toxic effects","volume":"44","author":"Engel","year":"1996","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.bbr.2009.06.008_bib92","first-page":"67","article-title":"The neurochemistry of Alzheimer's disease","volume":"97","author":"Engelborghs","year":"1997","journal-title":"Acta Neurol Belg"},{"key":"10.1016\/j.bbr.2009.06.008_bib93","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/j.1582-4934.2008.00314.x","article-title":"Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease","volume":"12","author":"Farfara","year":"2008","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib94","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/00006231-200505000-00005","article-title":"123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson's disease with unilateral symptoms","volume":"26","author":"Filippi","year":"2005","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.bbr.2009.06.008_bib95","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/(SICI)1098-2396(199806)29:2<128::AID-SYN4>3.0.CO;2-9","article-title":"Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters","volume":"29","author":"Fischman","year":"1998","journal-title":"Synapse"},{"key":"10.1016\/j.bbr.2009.06.008_bib96","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1212\/WNL.54.9.1768","article-title":"PET measures of benzodiazepine receptors in progressive supranuclear palsy","volume":"54","author":"Foster","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.bbr.2009.06.008_bib97","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/ana.410400609","article-title":"Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging","volume":"40","author":"Frey","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib98","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000117090","article-title":"Corticobasal degeneration: neuropsychological assessment and dopamine D2 receptor SPECT analysis","volume":"35","author":"Frisoni","year":"1995","journal-title":"Eur Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib99","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/ana.410340331","article-title":"Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease","volume":"34","author":"Frost","year":"1993","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib100","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/ana.20688","article-title":"Widespread decrease of nicotinic acetylcholine receptors in Parkinson's disease","volume":"59","author":"Fujita","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib101","first-page":"467","article-title":"Comparison of iodine-123-iomazenil SPECT and technetium-99m-HMPAO-SPECT in Alzheimer's disease","volume":"38","author":"Fukuchi","year":"1997","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib102","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1002\/mds.21062","article-title":"123I-Ioflupane SPECT in the diagnosis of suspected psychogenic Parkinsonism","volume":"21","author":"Gaig","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.bbr.2009.06.008_bib103","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1631\/jzus.2005.B0022","article-title":"Investigating the role of 99mTc-TRODAT-1 SPECT imaging in idiopathic Parkinson's disease","volume":"6","author":"Geng","year":"2005","journal-title":"J Zhejiang Univ Sci B"},{"key":"10.1016\/j.bbr.2009.06.008_bib104","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/mds.20162","article-title":"In vivo imaging of microglial activation with [11C](R)-PK11195 PET in corticobasal degeneration","volume":"19","author":"Gerhard","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.bbr.2009.06.008_bib105","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.nbd.2005.08.002","article-title":"In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease","volume":"21","author":"Gerhard","year":"2006","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.bbr.2009.06.008_bib106","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/mds.20668","article-title":"In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy","volume":"21","author":"Gerhard","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.bbr.2009.06.008_bib107","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/mds.10092","article-title":"[123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease","volume":"17","author":"Gerschlager","year":"2002","journal-title":"Mov Disord"},{"key":"10.1016\/j.bbr.2009.06.008_bib108","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/jnnp.73.5.517","article-title":"Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging","volume":"73","author":"Ghaemi","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.bbr.2009.06.008_bib109","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/ana.410400610","article-title":"Decreased striatal monoaminergic terminals in olivopontocerebellar atrophy and multiple system atrophy demonstrated with positron emission tomography","volume":"40","author":"Gilman","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib110","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/1531-8249(199906)45:6<769::AID-ANA11>3.0.CO;2-G","article-title":"Decreased striatal monoaminergic terminals in multiple system atrophy detected with positron emission tomography","volume":"45","author":"Gilman","year":"1999","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib111","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/ana.20088","article-title":"Striatal monoamine terminals in Lewy body dementia and Alzheimer's disease","volume":"55","author":"Gilman","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib112","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/brain\/120.3.503","article-title":"PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease","volume":"120","author":"Ginovart","year":"1997","journal-title":"Brain"},{"key":"10.1016\/j.bbr.2009.06.008_bib113","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF02335751","article-title":"Dopamine D2 receptor imaging with SPECT using IBZM in 16 patients with Parkinson disease","volume":"14","author":"Giobbe","year":"1993","journal-title":"Ital J Neurol Sci"},{"key":"10.1016\/j.bbr.2009.06.008_bib114","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1750-3639.1991.tb00671.x","article-title":"Tau proteins and neurofibrillary degeneration","volume":"1","author":"Goedert","year":"1991","journal-title":"Brain Pathol"},{"key":"10.1016\/j.bbr.2009.06.008_bib115","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/brain\/awg035","article-title":"Dopamine release during sequential finger movements in health and Parkinson's disease: a PET study","volume":"126","author":"Goerendt","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.bbr.2009.06.008_bib116","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000197889","article-title":"Dementia with Lewy bodies: clinical diagnosis and therapeutic approach","volume":"24","author":"Gold","year":"2009","journal-title":"Front Neurol Neurosci"},{"key":"10.1016\/j.bbr.2009.06.008_bib117","first-page":"2207","article-title":"PET of peripheral benzodiazepine binding sites in the microgliosis of Alzheimer's disease","volume":"36","author":"Groom","year":"1995","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib118","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1468-1331.2007.01727.x","article-title":"Brain serotonin transporter binding in non-depressed patients with Parkinson's disease","volume":"14","author":"Guttman","year":"2007","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib119","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/1531-8257(200101)16:1<124::AID-MDS1007>3.0.CO;2-R","article-title":"[123I]beta-CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients","volume":"16","author":"Haapaniemi","year":"2001","journal-title":"Mov Disord"},{"key":"10.1016\/j.bbr.2009.06.008_bib120","first-page":"99","article-title":"Regional kinetics of [11C]methylspiperone in the brain studied by positron emission tomography in patients with Parkinson's disease","volume":"45","author":"H\u00e4gglund","year":"1987","journal-title":"Adv Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib121","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1600-0404.1987.tb07900.x","article-title":"Dopamine receptor properties in Parkinson's disease and Huntington's chorea evaluated by positron emission tomography using 11C-N-methyl-spiperone","volume":"75","author":"H\u00e4gglund","year":"1987","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.bbr.2009.06.008_bib122","first-page":"125","article-title":"Dopamine transporter SPECT in patients with Parkinson's disease","volume":"37","author":"Hamano","year":"2000","journal-title":"Kaku Igaku"},{"key":"10.1016\/j.bbr.2009.06.008_bib123","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s00415-004-0564-3","article-title":"Sleep microstructure and neurodegeneration as measured by [123I]beta-CIT SPECT in treated patients with Parkinson's disease","volume":"251","author":"Happe","year":"2004","journal-title":"J Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib124","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/j.neurobiolaging.2007.04.011","article-title":"Reduced 5-HT2A receptor binding in patients with mild cognitive impairment","volume":"29","author":"Hasselbalch","year":"2008","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.bbr.2009.06.008_bib125","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s007020070009","article-title":"In-vivo measurements of regional acetylcholine esterase activity in degenerative dementia: comparison with blood flow and glucose metabolism","volume":"107","author":"Herholz","year":"2000","journal-title":"J Neural Transm"},{"key":"10.1016\/j.bbr.2009.06.008_bib126","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.neuroimage.2003.09.042","article-title":"In vivo study of acetylcholine esterase in basal forebrain, amygdala, and cortex in mild to moderate Alzheimer disease","volume":"21","author":"Herholz","year":"2004","journal-title":"Neuroimage"},{"key":"10.1016\/j.bbr.2009.06.008_bib127","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1503\/cmaj.070804","article-title":"Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease","volume":"17","author":"Herrmann","year":"2008","journal-title":"CMAJ"},{"key":"10.1016\/j.bbr.2009.06.008_bib128","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/00006231-199709000-00003","article-title":"Quantification of IBZM dopamine receptor SPET in de novo Parkinson patients before and during therapy","volume":"18","author":"Hertel","year":"1997","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.bbr.2009.06.008_bib129","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1055\/s-2008-1033028","article-title":"The determination of cerebral dopamine (D2) receptor density by using 123I-IBZM-SPECT in Parkinson disease patients","volume":"157","author":"Hierholzer","year":"1992","journal-title":"Rofo"},{"key":"10.1016\/j.bbr.2009.06.008_bib130","first-page":"141","article-title":"Brain SPECT with 123I-lisuride in patients with Parkinson's disease and controls","volume":"34","author":"Hierholzer","year":"1995","journal-title":"Nuklearmedizin"},{"key":"10.1016\/j.bbr.2009.06.008_bib131","first-page":"954","article-title":"Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes","volume":"39","author":"Hierholzer","year":"1998","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib132","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/ana.74","article-title":"Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene","volume":"49","author":"Hilker","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib133","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0304-3940(01)02529-0","article-title":"The striatal dopaminergic deficit is dependent on the number of mutant alleles in a family with mutations in the parkin gene: evidence for enzymatic parkin function in humans","volume":"323","author":"Hilker","year":"2002","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.bbr.2009.06.008_bib134","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1212\/01.wnl.0000191154.78131.f6","article-title":"Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways","volume":"65","author":"Hilker","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.bbr.2009.06.008_bib135","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1001\/jama.1985.03360210079035","article-title":"Muscarinic acetylcholine receptors in Alzheimer's disease. In vivo imaging with iodine 123-labeled 3-quinuclidinyl-4-iodobenzilate and emission tomography","volume":"254","author":"Holman","year":"1985","journal-title":"JAMA"},{"key":"10.1016\/j.bbr.2009.06.008_bib136","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/ana.410340114","article-title":"Positron emission tomography measures of benzodiazepine receptors in Huntington's disease","volume":"34","author":"Holthoff","year":"1993","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib137","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/mds.20702","article-title":"Nigral degeneration and striatal dopaminergic dysfunction in idiopathic and Parkin-linked Parkinson's disease","volume":"21","author":"Hu","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.bbr.2009.06.008_bib138","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1212\/WNL.55.10.1575","article-title":"18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies","volume":"55","author":"Hu","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.bbr.2009.06.008_bib139","first-page":"1303","article-title":"Evaluation of early-stage Parkinson's disease with 99mTc-TRODAT-1 imaging","volume":"42","author":"Huang","year":"2001","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib140","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000047962","article-title":"Downregulation of striatal dopamine D2 receptors in advanced Parkinson's disease contributes to the development of motor fluctuation","volume":"47","author":"Hwang","year":"2002","journal-title":"Eur Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib141","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1212\/WNL.52.6.1206","article-title":"SPECT imaging of pre- and postsynaptic dopaminergic alterations in l-DOPA-untreated PD","volume":"52","author":"Ichise","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.bbr.2009.06.008_bib142","doi-asserted-by":"crossref","first-page":"11965","DOI":"10.1073\/pnas.90.24.11965","article-title":"Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease","volume":"90","author":"Innis","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbr.2009.06.008_bib143","first-page":"216","article-title":"Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease","volume":"37","author":"Ishikawa","year":"1996","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib144","first-page":"1760","article-title":"Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP\/SPECT and fluorine-18-FDOPA\/PET","volume":"37","author":"Ishikawa","year":"1996","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib145","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/BF03165027","article-title":"Assessment of dopamine metabolism in brain of patients with dementia by means of 18F-fluorodopa and PET","volume":"8","author":"Itoh","year":"1994","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib146","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/brain\/awf134","article-title":"Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-l-DOPA PET study","volume":"125","author":"Ito","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.bbr.2009.06.008_bib147","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/S0140-6736(96)09124-6","article-title":"Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease","volume":"349","author":"Iyo","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.bbr.2009.06.008_bib148","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","article-title":"Parkinson's disease: clinical features and diagnosis","volume":"79","author":"Jankovic","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.bbr.2009.06.008_bib149","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ana.410430614","article-title":"Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia","volume":"43","author":"Jeon","year":"1998","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib150","first-page":"65","article-title":"Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C] raclopride and [11C]N-methylspiperone","volume":"41","author":"Kaasinen","year":"2000","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib151","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1212\/WNL.54.7.1482","article-title":"Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's disease","volume":"54","author":"Kaasinen","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.bbr.2009.06.008_bib152","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1093\/brain\/124.6.1125","article-title":"Increased frontal [(18)F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex","volume":"124","author":"Kaasinen","year":"2001","journal-title":"Brain"},{"key":"10.1016\/j.bbr.2009.06.008_bib153","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/00006231-200102000-00006","article-title":"The optimal imaging time for [99Tcm]TRODAT-1\/SPET in normal subjects and patients with Parkinson's disease","volume":"22","author":"Kao","year":"2001","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.bbr.2009.06.008_bib154","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/BF02251475","article-title":"Positron emission tomography in degenerative disorders of the dopaminergic system","volume":"4","author":"Karbe","year":"1992","journal-title":"J Neural Transm Park Dis Dement Sect"},{"key":"10.1016\/j.bbr.2009.06.008_bib155","first-page":"829","article-title":"Evaluation of dopaminergic presynaptic function by [F-18] DOPA PET","volume":"47","author":"Kato","year":"2007","journal-title":"Rinsho Shinkeigaku"},{"key":"10.1016\/j.bbr.2009.06.008_bib156","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/ana.10475","article-title":"[123I]-FP-CIT-SPECT demonstrates dopaminergic deficit in orthostatic tremor","volume":"53","author":"Katzenschlager","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib157","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1056\/NEJM198604103141506","article-title":"Alzheimer's disease","volume":"314","author":"Katzman","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib158","first-page":"391","article-title":"Impairment of benzodiazepine receptor in Parkinson's disease evaluated by 123I-iomazenil SPECT","volume":"33","author":"Kawabata","year":"1996","journal-title":"Kaku Igaku"},{"key":"10.1016\/j.bbr.2009.06.008_bib159","first-page":"244","article-title":"Evaluation of benzodiazepine receptor in the cerebral cortex of Parkinson's disease using 123I-iomazenil SPECT","volume":"55","author":"Kawabata","year":"1997","journal-title":"Nippon Rinsho"},{"key":"10.1016\/j.bbr.2009.06.008_bib160","first-page":"47","article-title":"New insight into the analysis of 6-[18F]fluoro-l-DOPA PET dynamic data in brain tissue without an irreversible compartment: comparative study of the Patlak and Logan analyses","volume":"21","author":"Kawatsu","year":"2003","journal-title":"Radiat Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib161","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1136\/jnnp.74.11.1567","article-title":"A randomised placebo controlled study to assess the effects of cholinergic treatment on muscarinic receptors in Alzheimer's disease","volume":"74","author":"Kemp","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.bbr.2009.06.008_bib162","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1460-9568.2003.02716.x","article-title":"Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer's disease","volume":"18","author":"Kemppainen","year":"2003","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.bbr.2009.06.008_bib163","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1073\/pnas.0510237103","article-title":"Serotonin 1A receptors in the living brain of Alzheimer's disease patients","volume":"103","author":"Kepe","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbr.2009.06.008_bib164","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/ana.10417","article-title":"Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study","volume":"52","author":"Khan","year":"2002","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib165","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1093\/brain\/awf237","article-title":"Progression of nigrostriatal dysfunction in a parkin kindred: an DOPA PET and clinical study","volume":"125","author":"Khan","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.bbr.2009.06.008_bib166","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1212\/01.WNL.0000148725.48740.6D","article-title":"Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation","volume":"64","author":"Khan","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.bbr.2009.06.008_bib167","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1093\/brain\/awh667","article-title":"Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data","volume":"128","author":"Khan","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.bbr.2009.06.008_bib168","first-page":"1703","article-title":"Imaging and quantitation of dopamine transporters with iodine-123-IPT in normal and Parkinson's disease subjects","volume":"38","author":"Kim","year":"1997","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib169","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/mds.10042","article-title":"Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP","volume":"17","author":"Kim","year":"2002","journal-title":"Mov Disord."},{"key":"10.1016\/j.bbr.2009.06.008_bib170","first-page":"870","article-title":"Serotonin transporters in the midbrain of Parkinson's disease patients: a study with 123I-beta-CIT SPECT","volume":"44","author":"Kim","year":"2003","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib171","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJM198804073181402","article-title":"Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications","volume":"318","author":"Kish","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib172","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/33416","article-title":"Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism","volume":"392","author":"Kitada","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.bbr.2009.06.008_bib173","first-page":"49","article-title":"Benzodiazepine receptor and cerebral blood flow in early Alzheimer's disease\u2014SPECT study using 123I-iomazenil and 123I-IMP","volume":"33","author":"Kitamura","year":"1996","journal-title":"Kaku Igaku"},{"key":"10.1016\/j.bbr.2009.06.008_bib174","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1002\/mds.21004","article-title":"Dopamine transporters, D2 receptors, and glucose metabolism in corticobasal degeneration","volume":"21","author":"Klaffke","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.bbr.2009.06.008_bib175","first-page":"1216","article-title":"Lateralized differences in iodine-123-IBZM uptake in the basal ganglia in asymmetric Parkinson's disease","volume":"36","author":"Knable","year":"1995","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib176","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1007\/s00259-004-1578-x","article-title":"Imaging of dopamine transporters and D2 receptors in patients with Parkinson's disease and multiple system atrophy","volume":"31","author":"Knudsen","year":"2004","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.bbr.2009.06.008_bib177","first-page":"936","article-title":"11C-DTBZ and 18F-FDG PET measures in differentiating dementias","volume":"46","author":"Koeppe","year":"2005","journal-title":"J Nucl Med"},{"issue":"Suppl 1","key":"10.1016\/j.bbr.2009.06.008_bib178","first-page":"67","article-title":"Differentiating Alzheimer's disease from dementia with Lewy bodies and Parkinson's disease with (+)-[11C]dihydrotetrabenazine positron emission tomography","volume":"4","author":"Koeppe","year":"2008","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.bbr.2009.06.008_bib179","first-page":"1184","article-title":"Three cases of clinically diagnosed corticobasal degeneration\u2013neuroimaging studies with MRI, SPECT and PET","volume":"35","author":"Koide","year":"1995","journal-title":"Rinsho Shinkeigaku"},{"key":"10.1016\/j.bbr.2009.06.008_bib180","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/mds.20857","article-title":"Oral methylphenidate fails to elicit significant changes in extracellular putaminal dopamine levels in Parkinson's disease patients: positron emission tomographic studies","volume":"21","author":"Koochesfahani","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.bbr.2009.06.008_bib181","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1212\/WNL.56.10.1355","article-title":"Familial parkinsonism with synuclein pathology: clinical and PET studies of A30P mutation carriers","volume":"56","author":"Kr\u00fcger","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.bbr.2009.06.008_bib182","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/ana.410400309","article-title":"In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease","volume":"40","author":"Kuhl","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib183","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1212\/WNL.52.4.691","article-title":"In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease","volume":"52","author":"Kuhl","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.bbr.2009.06.008_bib184","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/sj.jcbfm.9600202","article-title":"Dopamine storage capacity in caudate and putamen of patients with early Parkinson's disease: correlation with asymmetry of motor symptoms","volume":"26","author":"Kumakura","year":"2006","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.bbr.2009.06.008_bib185","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1093\/brain\/awg270","article-title":"[11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease","volume":"126","author":"Kumar","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.bbr.2009.06.008_bib186","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/1531-8249(200005)47:5<644::AID-ANA13>3.0.CO;2-C","article-title":"Benzodiazepine receptor binding in Huntington's disease: [11C]flumazenil uptake measured using positron emission tomography","volume":"47","author":"Kunig","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib187","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/00006231-200404000-00005","article-title":"Imaging early-stage corticobasal degeneration with [99mTc]TRODAT-1 SPET","volume":"25","author":"Lai","year":"2004","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.bbr.2009.06.008_bib188","first-page":"1263","article-title":"PET studies on brain monoamine transporters with carbon-11-beta-CIT in Parkinson's disease","volume":"36","author":"Laihinen","year":"1995","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib189","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.pscychresns.2007.07.003","article-title":"Serotonin-1A receptors in frontotemporal dementia compared with controls","volume":"156","author":"Lanct\u00f4t","year":"2007","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.bbr.2009.06.008_bib190","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/JGP.0b013e3180488325","article-title":"A positron emission tomography study of 5-hydroxytryptamine-1A receptors in Alzheimer disease","volume":"15","author":"Lanct\u00f4t","year":"2007","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.bbr.2009.06.008_bib191","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/00004647-200003000-00001","article-title":"Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review","volume":"20","author":"Laruelle","year":"2000","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.bbr.2009.06.008_bib192","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1001\/archneur.1993.00540050059016","article-title":"Imaging of D2 dopamine receptors of patients with Parkinson's disease using single photon emission computed tomography and iodobenzamide I 123","volume":"50","author":"Laulumaa","year":"1993","journal-title":"Arch Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib193","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s004150050534","article-title":"Fluorodopa uptake and glucose metabolism in early stages of corticobasal degeneration","volume":"246","author":"Laureys","year":"1999","journal-title":"J Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib194","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/1531-8249(200004)47:4<493::AID-ANA13>3.0.CO;2-4","article-title":"In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease","volume":"47","author":"Lee","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib195","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/jnnp.49.8.853","article-title":"Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography","volume":"49","author":"Leenders","year":"1986","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.bbr.2009.06.008_bib196","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1001\/archneur.1990.00530120034007","article-title":"The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease","volume":"47","author":"Leenders","year":"1990","journal-title":"Arch Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib197","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s00115-007-2312-2","article-title":"Treatment for dementia in parkinsonian syndromes. Efficacy of cholinesterase inhibitors","volume":"79","author":"Liepelt","year":"2008","journal-title":"Nervenarzt"},{"key":"10.1016\/j.bbr.2009.06.008_bib198","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/jcbfm.1990.127","article-title":"Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(\u2212)-cocaine PET studies in human subjects","volume":"10","author":"Logan","year":"1990","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.bbr.2009.06.008_bib199","first-page":"1688","article-title":"123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism","volume":"45","author":"Lorberboym","year":"2004","journal-title":"J Nucl Med."},{"key":"10.1016\/j.bbr.2009.06.008_bib200","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.neurobiolaging.2004.08.005","article-title":"Alzheimer disease and Down syndrome: factors in pathogenesis","volume":"26","author":"Lott","year":"2005","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.bbr.2009.06.008_bib201","first-page":"49","article-title":"99mTc-TRODAT-1 imaging of multiple system atrophy","volume":"45","author":"Lu","year":"2004","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib202","first-page":"235","article-title":"Genetic and DAT imaging studies of familial parkinsonism in a Taiwanese cohort","volume":"70","author":"Lu","year":"2006","journal-title":"J Neural Transm Suppl"},{"key":"10.1016\/j.bbr.2009.06.008_bib203","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1097\/00006231-200211000-00003","article-title":"The feasibility of statistical parametric mapping for the analysis of positron emission tomography studies using 11C-2-beta-carbomethoxy-3-beta-(4-fluorophenyl)-tropane in patients with movement disorders","volume":"23","author":"Lucignani","year":"2002","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.bbr.2009.06.008_bib204","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/syn.10090","article-title":"Parametric mapping of [18F]FPCIT binding in early stage Parkinson's disease: a PET study","volume":"45","author":"Ma","year":"2002","journal-title":"Synapse"},{"key":"10.1016\/j.bbr.2009.06.008_bib205","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1212\/WNL.46.1.231","article-title":"[123I] beta-CIT\/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease","volume":"46","author":"Marek","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.bbr.2009.06.008_bib206","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/mds.22108","article-title":"Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: A 3-year European multicenter study with repeat [(123)I]FP-CIT SPECT","volume":"4","author":"Marshall","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.bbr.2009.06.008_bib207","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.neuroimage.2007.11.028","article-title":"In vivo SPECT imaging of vesicular acetylcholine transporter using [(123)I]-IBVM in early Alzheimer's disease","volume":"40","author":"Maz\u00e8re","year":"2008","journal-title":"Neuroimage"},{"key":"10.1016\/j.bbr.2009.06.008_bib208","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1474-4422(07)70057-1","article-title":"Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study","volume":"6","author":"McKeith","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib209","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1176\/ajp.156.12.1871","article-title":"PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders","volume":"156","author":"Meltzer","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.bbr.2009.06.008_bib210","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000197896","article-title":"Frontotemporal dementia: therapeutic interventions","volume":"24","author":"Mendez","year":"2009","journal-title":"Front Neurol Neurosci"},{"key":"10.1016\/j.bbr.2009.06.008_bib211","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.nbd.2007.09.004","article-title":"Extrastriatal monoamine neuron function in Parkinson's disease: an 18F-dopa PET study","volume":"29","author":"Moore","year":"2008","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.bbr.2009.06.008_bib212","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1136\/jnnp.59.6.597","article-title":"Clinical and [18F] dopa PET findings in early Parkinson's disease","volume":"59","author":"Morrish","year":"1995","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.bbr.2009.06.008_bib213","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1136\/jnnp.64.3.314","article-title":"Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with DOPA PET","volume":"64","author":"Morrish","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.bbr.2009.06.008_bib214","first-page":"584","article-title":"Binding of [99mTc]TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers","volume":"41","author":"Mozley","year":"2000","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib215","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1097\/00006231-199712000-00002","article-title":"2-[123I]-iodolisuride SPET visualizes dopaminergic loss in de-novo parkinsonian patients: is it a marker of striatal pre-synaptic degeneration?","volume":"18","author":"M\u00fcller","year":"1997","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.bbr.2009.06.008_bib216","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000007896","article-title":"[123I]beta-CIT SPECT visualizes dopamine transporter loss in de novo parkinsonian patients","volume":"39","author":"M\u00fcller","year":"1998","journal-title":"Eur Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib217","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s00415-006-0492-5","article-title":"Chorea-acanthocytosis in monozygotic twins: clinical findings and neuropathological changes as detected by diffusion tensor imaging, FDG-PET and (123)I-beta-CIT-SPECT","volume":"254","author":"M\u00fcller-Vahl","year":"2007","journal-title":"J Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib218","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/0024-3205(80)90469-5","article-title":"Striatal opiate receptors: pre- and postsynaptic localization","volume":"27","author":"Murrin","year":"1980","journal-title":"Life Sci"},{"key":"10.1016\/j.bbr.2009.06.008_bib219","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0022-510X(96)00168-2","article-title":"Brain 6-[18F]fluorodopa metabolism in early and late onset of Parkinson's disease studied by positron emission tomography","volume":"144","author":"Nagasawa","year":"1996","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.bbr.2009.06.008_bib220","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/brain\/awf013","article-title":"Two large British kindreds with familial Parkinson's disease: a clinico-pathological and genetic study","volume":"125","author":"Nicholl","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.bbr.2009.06.008_bib221","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00002093-199505000-00006","article-title":"Kinetic analysis of regional (S)(\u2212)11C-nicotine binding in normal and Alzheimer brains\u2013in vivo assessment using positron emission tomography","volume":"9","author":"Nordberg","year":"1995","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1016\/j.bbr.2009.06.008_bib222","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.neuropsychologia.2008.03.020","article-title":"Amyloid imaging in Alzheimer's disease","volume":"46","author":"Nordberg","year":"2008","journal-title":"Neuropsychologia"},{"key":"10.1016\/j.bbr.2009.06.008_bib223","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/1531-8249(200006)47:6<804::AID-ANA14>3.0.CO;2-F","article-title":"Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT","volume":"47","author":"Nurmi","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib224","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1097\/00004647-200011000-00010","article-title":"Reproducibility and effect of levodopa on dopamine transporter function measurements: a [18F]CFT PET study","volume":"20","author":"Nurmi","year":"2000","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.bbr.2009.06.008_bib225","first-page":"51","article-title":"The basal ganglia and disorders of movement: pathophysiological mechanisms","volume":"17","author":"Obeso","year":"2002","journal-title":"News Physiol Sci"},{"key":"10.1016\/j.bbr.2009.06.008_bib226","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1001\/archneur.61.6.919","article-title":"Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies","volume":"61","author":"O\u2019Brien","year":"2004","journal-title":"Arch Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib227","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/jnnp.2006.108209","article-title":"Alpha4beta2 nicotinic receptor status in Alzheimer's disease using 123I-5IA-85380 single-photon-emission computed tomography","volume":"78","author":"O\u2019Brien","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.bbr.2009.06.008_bib228","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/BF03164869","article-title":"Preserved benzodiazepine receptors in Alzheimer's disease measured with C-11 flumazenil PET and I-123 iomazenil SPECT in comparison with CBF","volume":"13","author":"Ohyama","year":"1999","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib229","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jns.2007.02.014","article-title":"Quantification of nicotinic acetylcholine receptors in Parkinson's disease with (123)I-5IA SPECT","volume":"256","author":"Oishi","year":"2007","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.bbr.2009.06.008_bib230","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF02984999","article-title":"A simple method for the detection of abnormal brain regions in Alzheimer's disease patients using [11C]MP4A: comparison with [123I]IMP SPECT","volume":"18","author":"Ota","year":"2004","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib231","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0022-510X(93)90218-N","article-title":"Cerebral glucose metabolism and striatal 18F-dopa uptake by PET in cases of chorea with or without dementia","volume":"115","author":"Otsuka","year":"1993","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.bbr.2009.06.008_bib232","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/BF03164771","article-title":"Differentiating between multiple system atrophy and Parkinson's disease by positron emission tomography with 18F-dopa and 18F-FDG","volume":"11","author":"Otsuka","year":"1997","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib233","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10072-006-0718-4","article-title":"Comparative analysis of visual and semi-quantitative assessment of striatal [123I]FP-CIT-SPET binding in Parkinson's disease","volume":"27","author":"Ottaviani","year":"2006","journal-title":"Neurol Sci"},{"key":"10.1016\/j.bbr.2009.06.008_bib234","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1552-6569.2002.tb00139.x","article-title":"Comparison of striatal dopamine D2 receptors in Parkinson's disease and progressive supranuclear palsy patients using [123I] iodobenzofuran single-photon emission computed tomography","volume":"12","author":"Oyanagi","year":"2002","journal-title":"J Neuroimaging"},{"key":"10.1016\/j.bbr.2009.06.008_bib235","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00415-006-0473-8","article-title":"Muscarinic acetylcholine receptor status in Alzheimer's disease assessed using (R, R) 123I-QNB SPECT","volume":"254","author":"Pakrasi","year":"2007","journal-title":"J Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib236","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/mds.10133","article-title":"[18F]-Dopa positron emission tomography imaging in early-stage, non-parkin juvenile parkinsonism","volume":"17","author":"Pal","year":"2002","journal-title":"Mov Disord"},{"key":"10.1016\/j.bbr.2009.06.008_bib237","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1353-8020(00)00026-2","article-title":"Positron emission tomography in pallido-ponto-nigral degeneration (PPND) family (frontotemporal dementia with parkinsonism linked to chromosome 17 and point mutation in tau gene)","volume":"7","author":"Pal","year":"2002","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.bbr.2009.06.008_bib238","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.nbd.2008.03.012","article-title":"A voxel-based PET study of dopamine transporters in Parkinson's disease: relevance of age at onset","volume":"31","author":"Panzacchi","year":"2008","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.bbr.2009.06.008_bib239","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1212\/WNL.55.10.1540","article-title":"A multicenter assessment of dopamine transporter imaging with DOPASCAN\/SPECT in parkinsonism","volume":"55","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.bbr.2009.06.008_bib240","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/brain\/awg119","article-title":"Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study","volume":"126","author":"Pavese","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.bbr.2009.06.008_bib241","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1212\/01.wnl.0000242888.30755.5d","article-title":"Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study","volume":"67","author":"Pavese","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.bbr.2009.06.008_bib242","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/mds.21971","article-title":"The current clinical management of Huntington's disease","volume":"23","author":"Phillips","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.bbr.2009.06.008_bib243","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1001\/archneur.58.11.1846","article-title":"Familial progressive supranuclear palsy: detection of subclinical cases using 18F-dopa and 18fluorodeoxyglucose positron emission tomography","volume":"58","author":"Piccini","year":"2001","journal-title":"Arch Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib244","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/ana.10526","article-title":"Endogenous dopamine release after pharmacological challenges in Parkinson's disease","volume":"53","author":"Piccini","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib245","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1136\/jnnp.70.5.657","article-title":"Benzodiazepine receptor quantification in Huntington's disease with [(123)I]omazenil and SPECT","volume":"70","author":"Pinborg","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.bbr.2009.06.008_bib246","first-page":"1711","article-title":"Iodine-123-epidepride-SPECT: studies in Parkinson's disease, multiple system atrophy and Huntington's disease","volume":"38","author":"Pirker","year":"1997","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib247","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/1531-8257(200011)15:6<1158::AID-MDS1015>3.0.CO;2-0","article-title":"[123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration","volume":"15","author":"Pirker","year":"2000","journal-title":"Mov Disord"},{"key":"10.1016\/j.bbr.2009.06.008_bib248","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/mds.1265","article-title":"Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study","volume":"17","author":"Pirker","year":"2002","journal-title":"Mov Disord"},{"key":"10.1016\/j.bbr.2009.06.008_bib249","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000116921","article-title":"Dopamine receptor SPET imaging in Parkinson's disease: a [123I]-IBZM and [99mTc]-HM-PAO study","volume":"33","author":"Pizzolato","year":"1993","journal-title":"Eur Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib250","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1212\/WNL.47.4.1065","article-title":"Reduced striatal dopamine receptors in Alzheimer's disease: single photon emission tomography study with the D2 tracer [123I]-IBZM","volume":"47","author":"Pizzolato","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.bbr.2009.06.008_bib251","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00702-004-0208-x","article-title":"Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients","volume":"112","author":"Plotkin","year":"2005","journal-title":"J Neural Transm"},{"issue":"7 Suppl","key":"10.1016\/j.bbr.2009.06.008_bib252","first-page":"65","article-title":"Treatments for Parkinson disease\u2014past achievements and current clinical needs","volume":"72","author":"Poewe","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.bbr.2009.06.008_bib253","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.expneurol.2008.07.021","article-title":"Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: An in vivo(11)C-raclopride PET study","volume":"214","author":"Politis","year":"2008","journal-title":"Exp Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib254","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1093\/brain\/awn244","article-title":"Hypothalamic involvement in Huntington's disease: an in vivo PET study","volume":"131","author":"Politis","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.bbr.2009.06.008_bib255","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/0006-8993(78)90895-8","article-title":"Localization of opiate receptors and enkephalins in the rat striatum in relationship with the nigrostriatal dopaminergic system: lesion studies","volume":"151","author":"Pollard","year":"1978","journal-title":"Brain Res"},{"key":"10.1016\/j.bbr.2009.06.008_bib256","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1212\/WNL.56.12.1759","article-title":"The nigrostriatal dopaminergic system in familial early onset parkinsonism with parkin mutations","volume":"56","author":"Portman","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.bbr.2009.06.008_bib257","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1097\/00006231-200111000-00007","article-title":"Quantitative analysis of striatal dopamine D2 receptors with 123 I-iodolisuride SPECT in degenerative extrapyramidal diseases","volume":"22","author":"Prunier","year":"2001","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.bbr.2009.06.008_bib258","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s004150050272","article-title":"Huntington's disease and other choreas","volume":"245","author":"Quinn","year":"1998","journal-title":"J Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib259","first-page":"1769","article-title":"PET measurement of cardiac and nigrostriatal denervation in Parkinsonian syndromes","volume":"47","author":"Raffel","year":"2006","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib260","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1093\/brain\/122.9.1637","article-title":"Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]dopa-PET study","volume":"122","author":"Rakshi","year":"1999","journal-title":"Brain"},{"key":"10.1016\/j.bbr.2009.06.008_bib261","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s002590100571","article-title":"Striatal dopamine transporter function in dementia with Lewy bodies and Parkinson's disease","volume":"28","author":"Ransmayr","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib262","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11940-009-0021-9","article-title":"Corticobasal degeneration","volume":"11","author":"Reich","year":"2009","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib263","first-page":"838","article-title":"Dopamine (D2) receptor SPECT with 123I-iodobenzamide (IBZM) in diagnosis of Parkinson syndrome","volume":"35","author":"Reiche","year":"1995","journal-title":"Radiologe"},{"key":"10.1016\/j.bbr.2009.06.008_bib264","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/brain\/awh445","article-title":"Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system","volume":"128","author":"Remy","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.bbr.2009.06.008_bib265","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/mds.870050114","article-title":"Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease","volume":"5","author":"Rinne","year":"1990","journal-title":"Mov Disord"},{"key":"10.1016\/j.bbr.2009.06.008_bib266","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/mds.870080203","article-title":"PET study on striatal dopamine D2 receptor changes during the progression of early Parkinson's disease","volume":"8","author":"Rinne","year":"1993","journal-title":"Mov Disord"},{"key":"10.1016\/j.bbr.2009.06.008_bib267","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/syn.890210202","article-title":"PETexamination of the monoamine transporter with [11C]beta-CIT and [11C]beta-CFT in early Parkinson's disease","volume":"21","author":"Rinne","year":"1995","journal-title":"Synapse"},{"key":"10.1016\/j.bbr.2009.06.008_bib268","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/ana.410370505","article-title":"Positron emission tomography studies on the dopaminergic system and striatal opioid binding in the olivopontocerebellar atrophy variant of multiple system atrophy","volume":"37","author":"Rinne","year":"1995","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib269","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1212\/WNL.50.1.152","article-title":"Striatal uptake of the dopamine reuptake ligand [11C]beta-CFT is reduced in Alzheimer's disease assessed by positron emission tomography","volume":"50","author":"Rinne","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.bbr.2009.06.008_bib270","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/syn.1042","article-title":"[(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease","volume":"40","author":"Rinne","year":"2001","journal-title":"Synapse"},{"key":"10.1016\/j.bbr.2009.06.008_bib271","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1212\/WNL.58.10.1489","article-title":"Striatal dopamine transporter and extrapyramidal symptoms in frontotemporal dementia","volume":"58","author":"Rinne","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.bbr.2009.06.008_bib272","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1136\/jnnp.74.1.113","article-title":"Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer's disease","volume":"74","author":"Rinne","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.bbr.2009.06.008_bib273","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0074-7742(07)82012-5","article-title":"Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder?","volume":"82","author":"Rogers","year":"2007","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.bbr.2009.06.008_bib274","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1136\/jnnp.67.3.345","article-title":"Progressive frontal gait disturbance with atypical Alzheimer's disease and corticobasal degeneration","volume":"67","author":"Rossor","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.bbr.2009.06.008_bib275","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/WCO.0b013e328304b692","article-title":"Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments","volume":"21","author":"Roze","year":"2008","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib276","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/ana.410320503","article-title":"The identification of presymptomatic parkinsonism: clinical and DOPA positron emission tomography studies in an Irish kindred","volume":"32","author":"Sawle","year":"1992","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib277","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/brain\/116.4.853","article-title":"Asymmetrical pre-synaptic and post-synaptic changes in the striatal dopamine projection in dopa naive parkinsonism: diagnostic implications of the D2 receptor status","volume":"116","author":"Sawle","year":"1993","journal-title":"Brain"},{"key":"10.1016\/j.bbr.2009.06.008_bib278","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1093\/brain\/awh150","article-title":"Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism","volume":"127","author":"Scherfler","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.bbr.2009.06.008_bib279","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/brain\/awh485","article-title":"Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease","volume":"128","author":"Scherfler","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.bbr.2009.06.008_bib280","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/mds.20811","article-title":"Upregulation of dopamine D2 receptors in dopaminergic drug-naive patients with Parkin gene mutations","volume":"21","author":"Scherfler","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.bbr.2009.06.008_bib281","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1007\/s00259-004-1465-5","article-title":"The dopamine D2 receptor ligand 18F-desmethoxyfallypride: an appropriate fluorinated PET tracer for the differential diagnosis of parkinsonism","volume":"31","author":"Schreckenberger","year":"2004","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.bbr.2009.06.008_bib282","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1136\/jnnp.57.9.1047","article-title":"Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT","volume":"57","author":"Schulz","year":"1994","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.bbr.2009.06.008_bib283","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0301-0082(96)00015-9","article-title":"Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae","volume":"49","author":"Schwarting","year":"1996","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.bbr.2009.06.008_bib284","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0301-0082(96)00040-8","article-title":"The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments","volume":"50","author":"Schwarting","year":"1996","journal-title":"Prog Neurobiol"},{"issue":"Suppl 6","key":"10.1016\/j.bbr.2009.06.008_bib285","first-page":"17","article-title":"123I-iodobenzamide-SPECT in 83 patients with de novo parkinsonism","volume":"43","author":"Schwarz","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.bbr.2009.06.008_bib286","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/mds.870130107","article-title":"123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism","volume":"13","author":"Schwarz","year":"1998","journal-title":"Mov Disord"},{"key":"10.1016\/j.bbr.2009.06.008_bib287","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0925-4927(98)00026-2","article-title":"Educed striatal dopaminergic innervation shown by IPT and SPECT in patients under neuroleptic treatment: need for levodopa therapy?","volume":"83","author":"Schwarz","year":"1998","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.bbr.2009.06.008_bib288","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1159\/000105159","article-title":"Evaluation of dopaminergic function in frontotemporal dementia using I-FP-CIT single photon emission computed tomography","volume":"4","author":"Sedaghat","year":"2007","journal-title":"Neurodegener Dis"},{"key":"10.1016\/j.bbr.2009.06.008_bib289","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/BF02191583","article-title":"Dopamine D1 receptor number\u2014a sensitive PET marker for early brain degeneration in Huntington's disease","volume":"243","author":"Sedvall","year":"1994","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.bbr.2009.06.008_bib290","first-page":"1500","article-title":"Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients","volume":"39","author":"Seibyl","year":"1998","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib291","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/mds.20229","article-title":"Comparison of diffusion-weighted imaging and [123I]IBZM-SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease","volume":"19","author":"Seppi","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.bbr.2009.06.008_bib292","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1001\/archneur.63.8.1154","article-title":"Topography of dopamine transporter availability in progressive supranuclear palsy: a voxelwise [123I]beta-CIT SPECT analysis","volume":"63","author":"Seppi","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib293","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1590\/S0004-282X2006000400021","article-title":"Neuroimaging of the dopamine transporter in Parkinson's disease: first study using [99mTc]-TRODAT-1 and SPECT in Brazil","volume":"64","author":"Shih","year":"2006","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.bbr.2009.06.008_bib294","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/mds.21315","article-title":"Higher nigrostriatal dopamine neuron loss in early than late onset Parkinson's disease?\u2014a [99mTc]-TRODAT-1 SPECT study","volume":"22","author":"Shih","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.bbr.2009.06.008_bib295","first-page":"488","article-title":"Dopamine D1 and D2 receptors in Parkinson's disease and striatonigral degeneration determined by PET","volume":"60","author":"Shinotoh","year":"1993","journal-title":"Adv Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib296","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/jnnp.56.5.467","article-title":"Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: a positron emission tomography study","volume":"56","author":"Shinotoh","year":"1993","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.bbr.2009.06.008_bib297","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/1531-8249(200008)48:2<194::AID-ANA9>3.0.CO;2-X","article-title":"Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease: a positron emission tomography study","volume":"48","author":"Shinotoh","year":"2000","journal-title":"Ann Neurol"},{"issue":"Suppl 1","key":"10.1016\/j.bbr.2009.06.008_bib298","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/00002093-200000001-00017","article-title":"Brain acetylcholinesterase activity in Alzheimer disease measured by positron emission tomography","volume":"14","author":"Shinotoh","year":"2000","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1016\/j.bbr.2009.06.008_bib299","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1749-6632.2003.tb07097.x","article-title":"The amygdala and Alzheimer's disease: positron emission tomographic study of the cholinergic system","volume":"985","author":"Shinotoh","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.bbr.2009.06.008_bib300","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.parkreldis.2004.12.004","article-title":"Early-onset Parkinson's disease in a Chinese population: 99mTc-TRODAT-1 SPECT, Parkin gene analysis and clinical study","volume":"11","author":"Shyu","year":"2005","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.bbr.2009.06.008_bib301","first-page":"594","article-title":"Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging","volume":"45","author":"Silverman","year":"2004","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib302","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00213-003-1700-y","article-title":"123I-beta-CIT SPECT demonstrates increased presynaptic dopamine transporter binding sites in basal ganglia in vivo in schizophrenia","volume":"173","author":"Sj\u00f8holm","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bbr.2009.06.008_bib303","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/0006-8993(83)90045-8","article-title":"Retrograde changes in cholinergic neurons in the basal forebrain of the rat following cortical damage","volume":"289","author":"Sofroniew","year":"1983","journal-title":"Brain Res"},{"key":"10.1016\/j.bbr.2009.06.008_bib304","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/BF01367587","article-title":"Reduced cortical distribution volume of iodine-123 iomazenil in Alzheimer's disease as a measure of loss of synapses","volume":"23","author":"Soricelli","year":"1996","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib305","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/00004647-200104000-00015","article-title":"A reversible tracer analysis approach to the study of effective dopamine turnover","volume":"21","author":"Sossi","year":"2001","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.bbr.2009.06.008_bib306","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/00004647-200202000-00011","article-title":"Increase in dopamine turnover occurs early in Parkinson's disease: evidence from a new modeling approach to PET 18 F-fluorodopa data","volume":"22","author":"Sossi","year":"2002","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.bbr.2009.06.008_bib307","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1097\/01.WCB.0000126563.85360.75","article-title":"Changes of dopamine turnover in the progression of Parkinson's disease as measured by positron emission tomography: their relation to disease-compensatory mechanisms","volume":"24","author":"Sossi","year":"2004","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.bbr.2009.06.008_bib308","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/00006231-200005000-00002","article-title":"[123I] beta-CIT binding and SPET compared with clinical diagnosis in parkinsonism","volume":"21","author":"Staffen","year":"2000","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.bbr.2009.06.008_bib309","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s007020070077","article-title":"Measuring the progression of idiopathic Parkinson's disease with [123I] beta-CIT SPECT","volume":"107","author":"Staffen","year":"2000","journal-title":"J Neural Transm"},{"key":"10.1016\/j.bbr.2009.06.008_bib310","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000069993","article-title":"In vivo dopamine pre-synaptic receptors and antioxidant activities in patients with Alzheimer's disease, dementia with Lewy bodies and in controls. A preliminary report","volume":"16","author":"Tabet","year":"2003","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.bbr.2009.06.008_bib311","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00702-006-0536-0","article-title":"Characterization of dopaminergic dysfunction in familial progressive supranuclear palsy: an (18)F-dopa PET study","volume":"114","author":"Tai","year":"2007","journal-title":"J Neural Transm"},{"key":"10.1016\/j.bbr.2009.06.008_bib312","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/BF02984560","article-title":"Significance of 123I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson's disease and related disorders: it can be a specific marker for Lewy body disease","volume":"18","author":"Taki","year":"2004","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib313","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/BF03006670","article-title":"Decreased striatal D2 receptor density associated with severe behavioral abnormality in Alzheimer's disease","volume":"17","author":"Tanaka","year":"2003","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib314","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/00006231-199108000-00005","article-title":"SPECT imaging of dopamine D2 receptors with 123I-IBZM: initial experience in controls and patients with Parkinson's syndrome and Wilson's disease","volume":"12","author":"Tatsch","year":"1991","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.bbr.2009.06.008_bib315","first-page":"415","article-title":"Relationship between clinical features of Parkinson's disease and presynaptic dopamine transporter binding assessed with [123I]IPT and single-photon emission tomography","volume":"24","author":"Tatsch","year":"1997","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib316","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1600-0404.1990.tb00926.x","article-title":"Striatal kinetics of [11C]-(+)-nomifensine and 6-[18F]fluoro-l-DOPA in Parkinson's disease measured with positron emission tomography","volume":"81","author":"Tedroff","year":"1990","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.bbr.2009.06.008_bib317","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1212\/WNL.46.5.1430","article-title":"Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET","volume":"46","author":"Tedroff","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.bbr.2009.06.008_bib318","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s11064-007-9517-4","article-title":"alpha4beta2-nicotinic receptor binding with 5-IA in Alzheimer's disease: methods of scan analysis","volume":"33","author":"Terri\u00e8re","year":"2008","journal-title":"Neurochem Res"},{"key":"10.1016\/j.bbr.2009.06.008_bib319","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1001\/archneur.61.11.1705","article-title":"Role of dopaminergic treatment in dopamine receptor down-regulation in advanced Parkinson disease: a positron emission tomographic study","volume":"61","author":"Thobois","year":"2004","journal-title":"Arch Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib320","first-page":"1171","article-title":"[123I]beta-CIT single-photon emission tomography in Parkinson's disease reveals a smaller decline in dopamine transporters with age than in controls","volume":"24","author":"Tissingh","year":"1997","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib321","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s004150050168","article-title":"Drug-naive patients with Parkinson's disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]beta-CIT SPECT","volume":"245","author":"Tissingh","year":"1998","journal-title":"J Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib322","first-page":"1143","article-title":"Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease","volume":"39","author":"Tissingh","year":"1998","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib323","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2967\/jnumed.108.050583","article-title":"Novel reference region model reveals increased microglial and reduced vascular binding of 11C-(R)-PK11195 in patients with Alzheimer's disease","volume":"49","author":"Tomasi","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib324","first-page":"303","article-title":"A phase 3 clinical trial of 123I-iomazenil, a new central-type benzodiazepine receptor imaging agent (Part 2)\u2013Report on clinical usefulness in diagnosis of degenerative neurological diseases and mental disorders","volume":"33","author":"Torizuka","year":"1996","journal-title":"Kaku Igaku"},{"key":"10.1016\/j.bbr.2009.06.008_bib325","first-page":"1299","article-title":"Progressive supranuclear paralysis. Quantification of dopamine D2 receptors using radionuclide tomography","volume":"23","author":"Tranquart","year":"1994","journal-title":"Presse Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib326","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1212\/01.wnl.0000271377.52421.4a","article-title":"Up-regulation of hippocampal serotonin metabolism in mild cognitive impairment","volume":"69","author":"Truchot","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.bbr.2009.06.008_bib327","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/brain\/118.3.689","article-title":"Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study","volume":"118","author":"Turjanski","year":"1995","journal-title":"Brain"},{"key":"10.1016\/j.bbr.2009.06.008_bib328","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1212\/WNL.49.3.717","article-title":"In vivo studies on striatal dopamine D1 and D2 site binding in l-DOPA-treated Parkinson's disease patients with and without dyskinesias","volume":"49","author":"Turjanski","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.bbr.2009.06.008_bib329","first-page":"408","article-title":"Differential diagnosis of Parkinson's disease and vascular parkinsonism by (99m)Tc-TRODAT-1","volume":"42","author":"Tzen","year":"2001","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib330","first-page":"292","article-title":"Study of the pre and post-synaptic dopaminergic system by DaTSCAN\/IBZM SPECT in the differential diagnosis of parkinsonism in 75 patients","volume":"19","author":"Vaamonde","year":"2004","journal-title":"Neurologia"},{"key":"10.1016\/j.bbr.2009.06.008_bib331","first-page":"276","article-title":"DaT-SCAN SPECT in the differential diagnosis of dementia with Lewy bodies and Alzheimer's disease","volume":"41","author":"Vaamonde-Gamo","year":"2005","journal-title":"Rev Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib332","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1212\/01.wnl.0000327523.52537.86","article-title":"Invited article: the Alzheimer disease-frontotemporal lobar degeneration spectrum","volume":"71","author":"Van der Zee","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.bbr.2009.06.008_bib333","first-page":"384","article-title":"Dual-tracer dopamine transporter and perfusion SPECT in differential diagnosis of parkinsonism using template-based discriminant analysis","volume":"47","author":"Van Laere","year":"2006","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib334","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1212\/01.wnl.0000176071.08694.cc","article-title":"Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease","volume":"65","author":"Van Oostrom","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.bbr.2009.06.008_bib335","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/archneur.1993.00540050063017","article-title":"Multiple system atrophy and progressive supranuclear palsy. Diminished striatal D2 dopamine receptor activity demonstrated by 123I-IBZM single photon emission computed tomography","volume":"50","author":"Van Royen","year":"1993","journal-title":"Arch Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib336","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/mds.1256","article-title":"[(123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy","volume":"16","author":"Varrone","year":"2001","journal-title":"Mov Disord"},{"key":"10.1016\/j.bbr.2009.06.008_bib337","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1212\/01.WNL.0000145765.19094.94","article-title":"Imaging of dopaminergic dysfunction with [123I]FP-CIT SPECT in early-onset parkin disease","volume":"63","author":"Varrone","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.bbr.2009.06.008_bib338","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s00259-008-0729-x","article-title":"Comparison between a dual-head and a brain-dedicated SPECT system in the measurement of the loss of dopamine transporters with [(123)I]FP-CIT","volume":"35","author":"Varrone","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.bbr.2009.06.008_bib339","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.pneurobio.2006.10.002","article-title":"The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: from pathology to imaging","volume":"80","author":"Venneti","year":"2006","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.bbr.2009.06.008_bib340","first-page":"2076","article-title":"Estimation of dopamine D2 receptor binding potential in the striatum with iodine-123-IBZM SPECT: technical and interobserver variability","volume":"34","author":"Verhoeff","year":"1993","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib341","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/0969-8051(95)02020-9","article-title":"Evaluation of [123I] beta-CIT binding with SPECT in controls, early and late Parkinson's disease","volume":"22","author":"Vermeulen","year":"1995","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.bbr.2009.06.008_bib342","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0197-4580(02)00137-9","article-title":"Imaging of the 5-HT2A system: age-, gender- and Alzheimer's disease-related findings","volume":"24","author":"Versijpt","year":"2003","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.bbr.2009.06.008_bib343","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000070857","article-title":"Assessment of neuroinflammation and microglial activation in Alzheimer's disease with radiolabelled PK11195 and single photon emission computed tomography. A pilot study","volume":"50","author":"Versijpt","year":"2003","journal-title":"Eur Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib344","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1159\/000115640","article-title":"Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes","volume":"59","author":"Vlaar","year":"2008","journal-title":"Eur Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib345","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0022-510X(00)00429-9","article-title":"Decreased striatal dopamine D2 receptor binding in amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA): D2 receptor down-regulation versus striatal cell degeneration","volume":"180","author":"Vogels","year":"2000","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.bbr.2009.06.008_bib346","first-page":"609","article-title":"Dementia with lewy bodies: a study of post-synaptic dopaminergic receptors with iodine-123 iodobenzamide single-photon emission tomography","volume":"24","author":"Walker","year":"1997","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib347","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0140-6736(99)01178-2","article-title":"In-vivo demonstration of dopaminergic degeneration in dementia with Lewy bodies","volume":"354","author":"Walker","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.bbr.2009.06.008_bib348","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1136\/jnnp.73.2.134","article-title":"Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand","volume":"73","author":"Walker","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.bbr.2009.06.008_bib349","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1212\/01.WNL.0000123248.39847.1D","article-title":"Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison","volume":"62","author":"Walker","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.bbr.2009.06.008_bib350","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1136\/jnnp.2006.110122","article-title":"Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy","volume":"78","author":"Walker","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.bbr.2009.06.008_bib351","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/ana.410400110","article-title":"Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease","volume":"40","author":"Weeks","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib352","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1001\/archneur.1991.00530140061018","article-title":"The distribution of cerebral muscarinic acetylcholine receptors in vivo in patients with dementia. A controlled study with 123IQNB and single photon emission computed tomography","volume":"48","author":"Weinberger","year":"1991","journal-title":"Arch Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib353","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1176\/jnp.4.3.239","article-title":"A comparison of FDG PET and IQNB SPECT in normal subjects and in patients with dementia","volume":"4","author":"Weinberger","year":"1992","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.bbr.2009.06.008_bib354","first-page":"124","article-title":"A differential diagnosis of Parkinsonism","volume":"2","author":"Weiner","year":"2005","journal-title":"Rev Neurol Dis"},{"key":"10.1016\/j.bbr.2009.06.008_bib355","first-page":"227","article-title":"Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease","volume":"46","author":"Weintraub","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib356","first-page":"393","article-title":"Sensitivity and specificity of 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects","volume":"45","author":"Weng","year":"2004","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib357","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1136\/jnnp.58.2.160","article-title":"Clinicopathological study of 35 cases of multiple system atrophy","volume":"58","author":"Wenning","year":"1995","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.bbr.2009.06.008_bib358","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/mds.870120203","article-title":"Multiple system atrophy: a review of 203 pathologically proven cases","volume":"12","author":"Wenning","year":"1997","journal-title":"Mov Disord"},{"issue":"Suppl 6","key":"10.1016\/j.bbr.2009.06.008_bib359","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/mds.10561","article-title":"Multiple system atrophy: an update","volume":"18","author":"Wenning","year":"2003","journal-title":"Mov Disord"},{"key":"10.1016\/j.bbr.2009.06.008_bib360","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.10427","article-title":"Plasticity of the nigropallidal pathway in Parkinson's disease","volume":"53","author":"Whone","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bbr.2009.06.008_bib361","doi-asserted-by":"crossref","first-page":"364","DOI":"10.4140\/TCP.n.2008.364","article-title":"Essential tremor: symptoms and treatment","volume":"23","author":"Wick","year":"2008","journal-title":"Consult Pharm"},{"key":"10.1016\/j.bbr.2009.06.008_bib362","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1096\/fj.02-0314fje","article-title":"Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson's disease","volume":"17","author":"Wilms","year":"2003","journal-title":"FASEB J"},{"key":"10.1016\/j.bbr.2009.06.008_bib363","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/mds.10184","article-title":"Clinical, 18F-dopa PET, and genetic analysis of an ethnic Chinese kindred with early-onset parkinsonism and parkin gene mutations","volume":"17","author":"Wu","year":"2002","journal-title":"Mov Disord"},{"key":"10.1016\/j.bbr.2009.06.008_bib364","doi-asserted-by":"crossref","first-page":"662","DOI":"10.5692\/clinicalneurol.48.662","article-title":"Case of a 30-year history of PARK6 \u2013 findings from functional imaging of the brain","volume":"48","author":"Yamashita","year":"2008","journal-title":"Rinsho Shinkeigaku"},{"key":"10.1016\/j.bbr.2009.06.008_bib365","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.biopsych.2008.04.021","article-title":"Increased binding of peripheral benzodiazepine receptor in Alzheimer's disease measured by positron emission tomography with [11C]DAA1106","volume":"64","author":"Yasuno","year":"2008","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.bbr.2009.06.008_bib366","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF03165414","article-title":"Cerebral muscarinic acetylcholinergic receptor measurement in Alzheimer's disease patients on 11C-N-methyl-4-piperidyl benzilate\u2014comparison with cerebral blood flow and cerebral glucose metabolism","volume":"12","author":"Yoshida","year":"1998","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.bbr.2009.06.008_bib367","first-page":"425","article-title":"Non-pharmacological and pharmacological treatment of the cognitive and behavioral symptoms of Alzheimer disease","volume":"23","author":"Zec","year":"2008","journal-title":"NeuroRehabilitation"},{"key":"10.1016\/j.bbr.2009.06.008_bib368","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1242\/dmm.003376","article-title":"Hunting for the function of Huntingtin","volume":"2","author":"Zheng","year":"2009","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.bbr.2009.06.008_bib369","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/1098-2396(20010315)39:4<275::AID-SYN1010>3.0.CO;2-3","article-title":"Assessment of muscarinic receptor concentrations in aging and Alzheimer disease with [11C]NMPB and PET","volume":"39","author":"Zubieta","year":"2001","journal-title":"Synapse"}],"container-title":["Behavioural Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432809003544?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432809003544?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:58:45Z","timestamp":1759064325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166432809003544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":369,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S0166432809003544"],"URL":"https:\/\/doi.org\/10.1016\/j.bbr.2009.06.008","relation":{},"ISSN":["0166-4328"],"issn-type":[{"value":"0166-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vivo imaging of synaptic function in the central nervous system","name":"articletitle","label":"Article Title"},{"value":"Behavioural Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbr.2009.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}